

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Scoping

#### STA Sacubitril valsartan for treating chronic heart failure

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The scoping workshop attendees noted that trials of treatments for chronic heart failure tend to recruit predominantly middle aged men. They further noted that hydralazine with nitrate is taken further along the treatment pathway than sacubitril valsartan and that hydralazine with nitrate is particularly recommended for people of African or Caribbean origin.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The generalisability of trial data to clinical practice in England is not an equalities issue. It will be discussed by the Appraisal Committee in its consideration of the evidence base but recommendations will not be made based on age or sex.

The scoping workshop attendees agrees that taking or not taking sacubitril valsartan would not preclude any group of people from receiving subsequent treatments.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Not applicable.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

None

**Approved by Associate Director (name):** .....Frances Sutcliffe.....

**Date:** 12/06/2015